Showing posts with label In Vitro Diagnostic Reagents Market. Show all posts
Showing posts with label In Vitro Diagnostic Reagents Market. Show all posts

Friday, July 26, 2019

In Vitro Diagnostics (IVD) Market by Technology, Application & Product - 2023


Factors such as increasing burden of chronic diseases (majorly due to the rising geriatric population), rising prevalence of infectious diseases, rising demand for early disease diagnosis using specialized tests, growing awareness on personalized medicine, increasing adoption of fully-automated instruments and automation in laboratories, and increasing adoption of point-of-care testing are driving the market growth.

The In Vitro Diagnostics Market is projected to reach USD 87.93 billion by 2023 from USD 68.12 billion in 2018, at a CAGR of 5.2%.

The oncology segment is expected to grow at the highest CAGR in the in vitro diagnostics market

The IVD market, by application is segmented into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology, and other applications (including genetic disease screening and human leukocyte antigen typing). The infectious diseases accounted for the largest share of this market, while oncology is expected to grow at the highest CAGR during the forecast period. The increasing number of cancer cases across the globe, growing demand for personalized medicine treatment, the increasing utility of biomarkers, and availability of funding for cancer research are some of the major factors propelling the growth of this application segment.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703

Point-of-care testing segment will continue to grow at higher rate till 2023. On the basis of end users, the in vitro diagnostics market is segmented into hospitals, laboratories, poit-of-care testing, patient self-testing, academic institutes, and other end users. The hospitals segment held the largest share of this market in 2017, while point-of-care testing segment is expected to register highest growth during the forecast period.

Regional Analysis:-

The in vitro diagnostics market, by region, has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2017, North America dominates the market; and Asia Pacific is expected to witness the highest CAGR during the forecast period, owing to factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups; continuously rising healthcare expenditure; increasing number of hospitals and clinical diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan.

Read More: - https://www.marketsandmarkets.com/PressReleases/ivd-in-vitro-diagnostics.asp

Top Key players:-
The top five players in this market hold a share of ~55–60% in 2017. Roche Diagnostics Limited (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific (US) are the leading players in this market.

Friday, June 28, 2019

In Vitro Diagnostics Market worth $87.93 Billion by 2023, at a CAGR of 5.2%


The In Vitro Diagnostics Market is projected to reach USD 87.93 billion by 2023 from USD 68.12 billion in 2018, at a CAGR of 5.2%.
Factors such as increasing burden of chronic diseases (majorly due to the rising geriatric population), rising prevalence of infectious diseases, rising demand for early disease diagnosis using specialized tests, growing awareness on personalized medicine, increasing adoption of fully-automated instruments and automation in laboratories, and increasing adoption of point-of-care testing are driving the market growth.
Moreover, the introduction of a new range of condition-specific markers and tests, with advances in genomics and proteomics, is expected to offer significant growth opportunities for market players during the forecast period.



In Vitro Diagnostics Market segmentation:

·         based on products
·         based on diseases
·         based on techniques,
·         based on application
·         based on end users
·         Based on regions.

The Major Players Opearting in the In Vitro Diagnostics Market:
The in vitro diagnostics market is highly competitive with several companies holding substantial market shares. The top five players in this market hold a share of ~55–60% in 2017. Roche Diagnostics Limited (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific (US) are the leading players in this market. Other players in this market are Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), Diasorin (Italy), Ortho-Clinical Diagnostics (US), and Qiagen (Germany). Major players in this market are continuously focusing on securing higher market shares through product launches, expansions, agreements, partnerships, collaborations, and acquisitions.

Geographical Detailed Analysis for In Vitro Diagnostics Market: The in vitro diagnostics market, by region, has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2017, North America dominates the market; and Asia Pacific is expected to witness the highest CAGR during the forecast period, owing to factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups; continuously rising healthcare expenditure; increasing number of hospitals and clinical diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan. Furthermore, the rapidly increasing geriatric population in Asian countries (particularly in Japan and China) and supportive government regulations will further aid the growth of this market during the forecast period.

Read More in Detailed (In Vitro Diagnostics Market):
https://www.marketsandmarkets.com/PressReleases/ivd-in-vitro-diagnostics.asp

Monday, June 24, 2019

In Vitro Diagnostics Market worth $87.93 Billion by 2023


The report "In Vitro Diagnostics Market by Product (Instruments, Reagents), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology) - Forecast to 2023", The report studies the global in vitro diagnostics market from the forecast period of 2018 to 2023. The market is projected to reach USD 87.93 billion by 2023 from USD 68.12 billion in 2018, at a CAGR of 5.2%.

Further more information in details about InVitro Diagnostics Market Best Chance to increase growth in revenue of your company.   

Factors such as increasing burden of chronic diseases (majorly due to the rising geriatric population), rising prevalence of infectious diseases, rising demand for early disease diagnosis using specialized tests, growing awareness on personalized medicine, increasing adoption of fully-automated instruments and automation in laboratories, and increasing adoption of point-of-care testing are driving the market growth. Moreover, the introduction of a new range of condition-specific markers and tests, with advances in genomics and proteomics, is expected to offer significant growth opportunities for market players during the forecast period.

Wednesday, June 19, 2019

In Vitro Diagnostics (IVD) Market by Technology, Application & Product - 2023


The report "In Vitro Diagnostic/IVD Market by Product (Instruments, Reagents), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology) - Forecast to 2023", The report studies the global in vitro diagnostics market from the forecast period of 2018 to 2023. The market is projected to reach USD 87.93 billion by 2023 from USD 68.12 billion in 2018, at a CAGR of 5.2%.

Further more information in details about InVitro Diagnostic/IVD Market Best Chance to increase growth in revenue of your company.
 
Factors such as increasing burden of chronic diseases (majorly due to the rising geriatric population), rising prevalence of infectious diseases, rising demand for early disease diagnosis using specialized tests, growing awareness on personalized medicine, increasing adoption of fully-automated instruments and automation in laboratories, and increasing adoption of point-of-care testing are driving the market growth. Moreover, the introduction of a new range of condition-specific markers and tests, with advances in genomics and proteomics, is expected to offer significant growth opportunities for market players during the forecast period.

Antibody Therapeutics Market : Driven by Advances in Biologics and Expanding Clinical Applications

The global antibody therapeutics market is projected to grow from USD 311.2 billion in 2026 to USD 597.1 billion by 2035, at a CAGR of 7.5...